The impact of drug-related QT prolongation on FDA regulatory decisions

被引:29
|
作者
Park, Eunjung [1 ]
Willard, James [1 ]
Bi, Daoqin [1 ]
Fiszman, Monica [1 ]
Kozeli, Devi [1 ]
Koerner, John [1 ]
机构
[1] US FDA, Div Cardiovasc & Renal Prod, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
关键词
QT prolongation; Safety warning; Drug approval;
D O I
10.1016/j.ijcard.2013.07.136
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:4975 / 4976
页数:2
相关论文
共 50 条